Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD
Recruiting
N/A
Interventional Study
Renal Insufficiency
Atherosclerosis
Dyslipidemia
Hypercholesterolemia
Cardiovascular Diseases
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 19 – 85
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 1,952 (estimated)
- Sponsor
- Yonsei University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The ULTRA-CKD trial is a prospective, randomized, open-label, multicenter trial designed to compare the efficacy and safety of moderate-intensity statin plus ezetimibe combination therapy versus high-intensity statin monotherapy in patients with chronic kidney disease (CKD) and concomitant atherosclerotic cardiovascular disease (ASCVD).
Patients with CKD are at very high risk for ASCVD. In this p…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Age 19-85 years.
2. Chronic kidney disease stage III, IV, or V (CKD-EPI eGFR \<60 / \<30 / \<15 mL/min/1.73 m² or on dialysis).
3. Established ASCVD, meeting at least one of the following:
* Prior acute coronary syndrome (myocardial infarction or unstable angina).
* St…
Contacts